Vitality Watch

⚠ Evidence note: Most trends in this area rest on anecdote and mechanism; where real evidence exists it is usually for narrower claims than the trend makes.

Mentioned 1× · first seen 16-nov-2026 · last seen 16-nov-2026

Alpha-Klotho Replacement Therapy

Current understanding

[anecdotal-biohack: trial-announcement signal, not outcome evidence] A first-in-human Phase I trial at GARM Próspera is assessing a single intravenous dose of alpha-Klotho mRNA therapy AKL003 in 20 healthy participants, with safety and exploratory biological-aging endpoints including DNA methylation. [mechanism-plausible] Aging benefit remains a hypothesis; the supplied finding reports no safety or efficacy results.

Evidence log

Open questions

Related

Contributing findings

clinicaltrials trial early
Phase I Trial of a Single Administration of aKLmRNA-Mediated Protein Replacement Therapy
12-nov-2026 novelty 4 per-area 4 introduces

build build 880 · 2bcef25 · 2026-11-18